Ownership Action Don’t Lie: Institutional Investors Negative on on Cormedix Inc Dropped

November 18, 2016 - By Marguerite Chambers   ·   0 Comments

Ownership Action Don't Lie: Institutional Investors  Negative on on Cormedix Inc  Dropped

Sentiment for Cormedix Inc (NYSEMKT:CRMD)

Cormedix Inc (NYSEMKT:CRMD) institutional sentiment increased to 0.64 in Q2 2016. Its up 0.10, from 0.54 in 2016Q1. The ratio is positive, as 19 active investment managers increased or opened new positions, while 35 sold and trimmed stock positions in Cormedix Inc. The active investment managers in our partner’s database now own: 4.22 million shares, down from 6.32 million shares in 2016Q1. Also, the number of active investment managers holding Cormedix Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 18 Reduced: 17 Increased: 9 New Position: 10.

CorMedix Inc. is a commercial pharmaceutical and medical device company. The company has a market cap of $66.84 million. The Firm in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It currently has negative earnings. The Firm has in-licensed the rights to develop and commercialize its product candidate, CRMD003 , which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

About 255,643 shares traded hands. CorMedix Inc. (NYSEMKT:CRMD) has declined 59.57% since April 18, 2016 and is downtrending. It has underperformed by 64.00% the S&P500.

According to Zacks Investment Research, “CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix’s goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications. The Company’s therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy. Its product pipeline includes: CRMD001, a unique formulation Deferiprone which is in development to prevent Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; CRMD002, a diagnostic test for urinary labile iron; CRMD003 (Neutrolin®, an antimicrobial/anticoagulant solution) is in development to prevent Catheter Related Bloodstream Infection; CRMD004, a pressure sensitive gel which has many uses, including extending the benefits of Neutrolin®. CorMedix Inc. is based in Summit, New Jersey.”

Bollard Group Llc holds 0.07% of its portfolio in CorMedix Inc. for 511,077 shares. Ray Gerald L & Associates Ltd owns 130,000 shares or 0.04% of their US portfolio. Moreover, Alpine Partners Vi Llc has 0.03% invested in the company for 27,565 shares. The Texas-based Bridgeway Capital Management Inc has invested 0.01% in the stock. Group One Trading L.P., a Illinois-based fund reported 303,325 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 5 insider purchases, and 7 sales for $281,545 net activity.

CRMD Company Profile

CorMedix Inc., incorporated on July 28, 2006, is a commercial pharmaceutical and medical device company. The Firm in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Firm has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

More news for CorMedix Inc. (NYSEMKT:CRMD) were recently published by: Valuewalk.com, which released: “Resonant Down 70%… Could CorMedix Inc. (CRMD) Be Next?” on April 13, 2015. Quotes.Wsj.com‘s article titled: “News CorMedix Inc.CRMD” and published on February 11, 2011 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marguerite Chambers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>